<DOC>
<DOCNO>EP-0610140</DOCNO> 
<TEXT>
<INVENTION-TITLE>
2-[4-(4-Azolylbutyl)-1-piperazinyl]-5-hydroxypyrimidin derivatives, their preparation and their use as medicines
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D23942	A61P2500	A61P2500	C07D40312	A61K31506	C07D40300	A61P2520	A61P2522	C07D23928	A61K31505	C07D23900	A61K31505	A61K31506	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	A61P	A61P	C07D	A61K	C07D	A61P	A61P	C07D	A61K	C07D	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D239	A61P25	A61P25	C07D403	A61K31	C07D403	A61P25	A61P25	C07D239	A61K31	C07D239	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
2-[4-(4-Azolylbutyl)-1-piperazinyl]pyrimidine derivatives, characterized in that they correspond to the general formula I 
<
IMAGE
>
 in which X2 represents a nitrogen atom or a C-R2 group, X4 represents a nitrogen atom or a C-R4 group and X5 represents a nitrogen atom or a C-R5 group, their process of preparation, their application as medicament and the pharmaceutical compositions comprising them.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
2-[4-(4-azolylbutyl)-1-piperazinyl]pyrimidine

derivatives, characterized in that they correspond to the
general formula I,



in which X
2
 represents a nitrogen atom or a C-R
2
 group, X
4

represents a nitrogen atom or a C-R
4
 group, X
5
 represents
a nitrogen atom or a C-R
5
 group, and R
2
, R
3
, R
4
 and R
5
,
which are identical or different, represent a hydrogen

atom, a halogen, a methyl radical, as well as their
physiologically acceptable salts.
Compounds corresponding to the general formula I
according to Claim 1, which are chosen from the

following:

2-{4-[4-(4-chloropyrazol-1-yl)butyl]-1-piperazinyl}-5-hydroxypyrimidine-1-piperazinyl]
pyrimidine
2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-hydroxypyrimidine
2-{4-[4-(4,5-dichloro-2 methylimidazol-1-yl)butyl]-1-piperazinyl}-5-hydroxypyrimidine

hydrochloride.
Process for preparing the compounds of general
formula I, according to Claims 1 and 2, characterized in

that the following operations are carried out:

oxidation of 5-benzyloxy-2-methylthiopyrimidine to
yield the corresponding sulphone of formula V, 


replacement of the methylsulphonyl radical with a
piperazine to yield the compound of formula VI,


reaction of compound VI with dibromobutane to yield
the corresponding spiro of formula VII,


reaction of 8-(5-benzyloxy-2-pyrimidinyl)-8-aza-5-azoniaspiro[4.5]decane

bromide with an azole of
general formula IX



in which X
2
, X
4
, X
5
, R
2
, R
3
, R
4
 and R
5
 have the meanings
indicated in Claim 1, to yield a compound of general

formula VIII

 
in which X
2
, X
4
, X
5
, R
2
, R
3
, R
4
 and R
5
 have the meanings
given earlier,
deprotection of the compound of general formula VIII
by hydrogenation of the benzyl group giving rise to

the formation of the compound of general formula I
in which X
2
, X
4
, X
5
, R
2
, R
3
, R
4
 and R
5
 have the
meanings given earlier.
Compound of general formula I, according to one
of Claims 1 and 2, as medicinal product.
Use of the compounds of general formula I and
their physiologically acceptable salts, according to one

of Claims 1 and 2, for the preparation of medicinal
products intended for the treatment of diseases which

affect the central nervous system of mammalians.
Pharmaceutical compositions characterized in that
they contain, in addition to a pharmaceutically

acceptable carrier, at least one compound of general
formula I or one of its physiologically acceptable salts,

according to one of Claims 1 and 2.
</CLAIMS>
</TEXT>
</DOC>
